tradingkey.logo
tradingkey.logo
Suchen

MaxCyte Inc

MXCT
Zur Watchlist hinzufügen
1.215USD
-0.015-1.22%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
130.15MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über MaxCyte Inc Unternehmen

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Inc Informationen

BörsenkürzelMXCT
Name des UnternehmensMaxCyte Inc
IPO-datumMar 29, 2016
CEOMasoud (Maher)
Anzahl der mitarbeiter114
WertpapierartOrdinary Share
GeschäftsjahresendeMar 29
Addresse9713 Key West Avenue,
StadtROCKVILLE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20850
Telefon13015175556
Websitehttps://www.maxcyte.com/
BörsenkürzelMXCT
IPO-datumMar 29, 2016
CEOMasoud (Maher)

Führungskräfte von MaxCyte Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
428.75K
+7.10%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
261.00K
+11.66%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
201.58K
+15.09%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
81.00K
+37.56%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
70.31K
+43.26%
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
428.75K
+7.10%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
261.00K
+11.66%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
201.58K
+15.09%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
-171.43%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
82.92K
+51.93%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
81.00K
+37.56%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von MaxCyte Inc?

Die fünf größten Anteilseigner von MaxCyte Inc sind: Mr. Stanley C. (Stan) Erck

Wie viele Institutionen halten Anteile an MaxCyte Inc (MXCT)?

Mit Stand vom 2026Q1 halten 292 Institutionen Anteile an MaxCyte Inc, mit einem Gesamtmarktwert von etwa 79.92M, was 74.61% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -18927703.00 gestiegen.

Was ist die größte Einnahmequelle von MaxCyte Inc?

Am 2026Q1 erzielte das Geschäft mit Product sales für MaxCyte Inc den höchsten Umsatz in Höhe von 18.69M, was 56.59% des Gesamtumsatzes entspricht.